![]() ![]() Once enrolled, the patient may pay $0 out-of-pocket for TRODELVY with maximum benefit of $25,000 per year.Įligible patients receive up to a maximum benefit of $25,000 per year. Patients must meet certain eligibility criteria to qualify for this program. *The TRODELVY Savings Program is not available to patients with any form of government insurance. Your healthcare provider may collect any remaining balance from you If approved, you or your healthcare provider will be reimbursed up to $25,000 annually by the TRODELVY Savings Program.You and your healthcare provider will receive an Explanation of Benefits, which shows how much your healthcare provider was reimbursed and how much you owe for the cost of TRODELVY.Your healthcare provider submits a claim to your insurance plan.Your healthcare provider purchases and administers TRODELVY.Your healthcare provider's office or TRODELVY ACCESS SUPPORT can help you apply.ĭownload the Patient Enrollment Form and then talk to your healthcare provider about the enrollment process: This Program does not support any claims covered, paid, or reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs.The Program only assists with cost of TRODELVY patient is responsible for cost-share of treatments and office visits.Patients may pay as little as $0 out-of-pocket for TRODELVY, which includes co-pay and coinsurance, up to $25,000 annually.Please see full Prescribing Information for SUNLENCA.If you are commercially or privately insured, the TRODELVY Savings Program* offers you savings on out-of-pocket expenses of TRODELVY 180-mg single-dose vials, up to $25,000 annually. Lactation: Individuals infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.An Antiretroviral Pregnancy Registry (APR) has been established. Pregnancy: There is insufficient human data on the use of SUNLENCA during pregnancy.Missed Dose: During the maintenance period, if more than 28 weeks have elapsed since the last injection and if clinically appropriate to continue SUNLENCA treatment, restart the initiation dosage regimen from Day 1, Option 1 or Option 2.Maintenance: 927 mg by subcutaneous injection every 26 weeks +/- 2 weeks from date of last injection.Day 15: 927 mg by subcutaneous injection. Day 8: 300 mg orally (1 x 300-mg tablet). Day 2: 600 mg orally (2 x 300-mg tablets). Initiation Option 2: Day 1: 600 mg orally (2 x 300-mg tablets).Initiation Option 1: Day 1: 927 mg by subcutaneous injection and 600 mg orally (2 x 300-mg tablets).Tablets may be taken with or without food. Dosage: Initiation with 1 of 2 options, followed by maintenance dosing once every 6 months.SUNLENCA may increase the exposure of drugs primarily metabolized by CYP3A, when initiated within 9 months after the last injection of SUNLENCA, which may increase the potential risk of adverse reactions. Drugs that strongly inhibit CYP3A, P-gp, and UGT1A1 together may significantly increase the concentration of SUNLENCA. Enzymes/transporters: Drugs that are strong or moderate inducers of CYP3A may significantly decrease the concentration of SUNLENCA.Prescribing information: Consult the full prescribing information for SUNLENCA for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments.Most common adverse reactions (incidence ≥3%, all grades) are injection site reactions (65%) and nausea (4%).Injection site reactions may occur, and nodules and indurations may be persistent.If discontinuing SUNLENCA, begin alternate suppressive ARV regimen within 28 weeks from last injection. If virologic failure occurs, switch to an alternative regimen if possible. Counsel patients regarding the dosing schedule because nonadherence could lead to loss of virologic response and development of resistance. SUNLENCA may increase exposure, and potential risk of adverse reactions, to drugs primarily metabolized by CYP3A initiated within 9 months after last injection. ![]() Long-acting properties and potential associated risks with SUNLENCA: Residual concentrations of SUNLENCA may remain in the systemic circulation of patients for up to 12 months or longer. ![]()
0 Comments
Leave a Reply. |